Vericiguat Patent Expiration
Vericiguat is Used for reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure. It was first introduced by Merck Sharp And Dohme Corp
Vericiguat Patents
Given below is the list of patents protecting Vericiguat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Verquvo | US9604948 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | Nov 26, 2032 | Merck Sharp Dohme |
| Verquvo | US10736896 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | May 19, 2031 | Merck Sharp Dohme |
| Verquvo | US11439642 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | May 19, 2031 | Merck Sharp Dohme |
| Verquvo | US8420656 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | May 19, 2031 | Merck Sharp Dohme |
| Verquvo | US8921377 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | May 19, 2031 | Merck Sharp Dohme |
| Verquvo | US9993476 | Substituted 5-flouro-1H-pyrazolopyridines and their use | May 19, 2031 | Merck Sharp Dohme |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vericiguat's patents.
Latest Legal Activities on Vericiguat's Patents
Given below is the list recent legal activities going on the following patents of Vericiguat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jan, 2024 | US10736896 |
| Second letter to regulating agency to determine regulatory review period | 15 Jun, 2023 | US8420656 |
| Second letter to regulating agency to determine regulatory review period | 15 Jun, 2023 | US9604948 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Oct, 2022 | US9604948 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Oct, 2022 | US8420656 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Sep, 2022 | US11439642 |
| Recordation of Patent Grant Mailed Critical | 13 Sep, 2022 | US11439642 |
| Email Notification Critical | 25 Aug, 2022 | US11439642 |
| Issue Notification Mailed Critical | 24 Aug, 2022 | US11439642 |
| Application Is Considered Ready for Issue Critical | 05 Aug, 2022 | US11439642 |
Vericiguat's Family Patents
